Upcoming event
Masterclass on Focal therapy for localised prostate cancer
Back

Tag: ASCO GU22

Phase 3 MAGNITUDE study

Association of RB1 mutational status with overall genomic landscape in neuroendocrine prostate cancer (NEPC)

PROpel trial

TheraP trial

Phase 3 MAGNITUDE study: First results of niraparib (NIRA) with abiraterone acetate and prednisone (AAP) as first-line therapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) with and without homologous recombination repair (HRR) gene alterations

Overall survival with darolutamide versus placebo in combination with androgen-deprivation therapy and docetaxel for metastatic hormone-sensitive prostate cancer in the phase 3 ARASENS trial

Association of RB1 mutational status with overall genomic landscape in neuroendocrine prostate cancer (NEPC)

PSMA PET and FDG PET as predictors of response and prognosis in a randomized phase 2 trial of 177Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic, castration-resistant prostate cancer (mCRPC) progressing after docetaxel (TheraP ANZUP 1603)

ASCO GU 2022 PCa abstracts recommendations

An AI-derived digital pathology-based biomarker to predict the benefit of androgen deprivation therapy in localized prostate cancer with validation in NRG/RTOG 9408